Mayne Pharma Group Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported revenue was AUD 183.59 million compared to AUD 157.15 million a year ago. Net income was AUD 117.25 million compared to net loss of AUD 281.29 million a year ago.

Basic loss per share from continuing operations was AUD 3.86 compared to AUD 2.55 a year ago. Diluted loss per share from continuing operations was AUD 3.86 compared to AUD 2.55 a year ago. Basic earnings per share was AUD 1.42 compared to basic loss per share of AUD 3.42 a year ago.

Diluted earnings per share was AUD 1.48 compared to diluted loss per share of AUD 3.42 a year ago.